Ed Arce joined WestPark Capital as a Managing Director to build a leading healthcare research platform. Mr. Arce covers emerging and small-to-midcap (SMID) biotechnology companies, focused on several therapeutic areas including hepatology; cardiovascular, renal & metabolism (CRM); inflammation & immunology (I&I); gastroenterology; and rare diseases. Mr. Arce brings nearly 20 years of experience with prior appointments at H.C. Wainwright, Roth Capital Partners, MLV & Co., Wedbush Securities and UBS Securities. In 2017, Mr. Arce was awarded the No. 1 Stock Picker in Biotechnology in the United States by the Thomson Reuters Analyst Awards.

Mr. Arce holds a B.S. in Civil Engineering and an MBA from Florida International University, an M.S. in Finance from Boston College, and an Executive Education Certificate by completing the Chief Financial Officer (CFO) Program from Columbia University. Mr. Arce holds the Series 7, 63, 86, and 87 registrations.